0000874015-20-000162.txt : 20201204
0000874015-20-000162.hdr.sgml : 20201204
20201204204928
ACCESSION NUMBER: 0000874015-20-000162
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201202
FILED AS OF DATE: 20201204
DATE AS OF CHANGE: 20201204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Monia Brett P
CENTRAL INDEX KEY: 0001537529
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 201371163
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
STREET 2: C/O ISIS PHARMACEUTICALS, INC.
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330336973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-12-02
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001537529
Monia Brett P
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE CT.
CARLSBAD,
CA
92010
1
1
0
0
Chief Executive Officer
Common Stock
2020-12-02
2020-12-02
4
M
0
21160.0
39.87
A
50039.0
D
Common Stock
2020-12-02
2020-12-02
4
S
0
21160.0
51.32
D
28879.0
D
Employee Stock Option (right to buy)
39.87
2020-12-02
2020-12-02
4
M
0
21160.0
0.0
D
2015-01-02
2021-01-01
Common Stock
0.0
23840.0
D
Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 3, 2019.
Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on April 3, 2019.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.70, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.
/s/Patrick R. O'Neil, attorney-in-fact
2020-12-04